Syneos Health has announced the acquisition of RxDataScience, a healthcare-focused data analytics, data management and artificial intelligence company.
RxDataScience’s product lifecycle solutions include scientific computing for R&D, patient journey, decentralized trials, RWE, predictive analytics and commercial market research. Additionally, RxDataScience offers a consulting-based model providing an iterative approach to develop and deliver analytics solution prototypes in six-to-eight-week sprints.
RxDataScience further scales Syneos Health’s data science abilities, adding capabilities and knowledge in data engineering and management. RxDataScience will be part of the Syneos Health Dynamic Assembly network.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.